Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal up3.620 +0.050 (+1.401%)
Research Report

08/09/2021 16:53

{I-bank focus}CS lowers Luye Pharma (02186) to HK$4.8

[ET Net News Agency, 8 September 2021] Credit Suisse lowered its target price for Luye
Pharma (02186) to HK$4.8 from HK$6.8 and downgraded its rating to "neutral" from
The research house said it revises down FY21/22/23 revenue estimates by -6%/-7%/-7%
mainly due to adjusted product sales of 2021. It also revises down FY21/22/23E EPS by
10%/19%/21% due to lower margin profile. (RC)

Remark: Real time quote last updated: 07/12/2021 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.